Poractant alfa

Poractant alfa

Clinical data
Trade names	Curosurf
AHFS/Drugs.com	monograph
Pregnancy category	N
Legal status	US: ℞-only
Routes of administration	endotracheal
Identifiers
CAS Number	129069-19-8 Y
ATC code	none

Poractant alfa is a pulmonary surfactant sold under the brand name Curosurf by Chiesi Farmaceutici. Poractant alfa is an extract of natural porcine lung surfactant. Acute Clinical. As with other surfactants marked improvement on oxygenation may occur within minutes of the administration of.

Pharmacology

Poractant alfa is measured into vials of 80 mg of surfactant (extract) that includes 76 mg of phospholipids and 1 mg of protein of which 0.2 mg is surfactant protein B (SP-B).

The amount of phospholipids is calculated from the content of phosphorus and contains 55 mg of phosphotidylcholine of which 30 mg is dipalmitoylphosphatidylcholine.

Considerations

Pulmonary hemorrhage

Pulmonary hemorrhage is a known complication of premature birth and very low birth-weight.

Other adverse effects

Transient episodes of bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage may occur.

Mechanism of action

Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during mechanical ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures.

A deficiency of pulmonary surfactant in preterm infants results in respiratory distress syndrome. Poractant alfa compensates for the surfactant deficiency and restores surface activity to the lung tissue.

Pharmacodynamics

Currently there is no human pharmacokinetic information available, only animal models have been published.

References

As with other surfactants, marked improvements in oxygation may occur within minutes of the administration of curosourf.